

## **Opdivo®** (nivolumab) – New indication

- On March 7, 2024, <u>Bristol Myers Squibb announced</u> the FDA approval of <u>Opdivo (nivolumab)</u>, in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC).
- Opdivo is also approved for:
  - Adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC
  - Treatment of adult patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy
  - Treatment of adult patients with locally advanced or metastatic UC who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy
- Refer to the Opdivo drug label for a complete list of its indications.
- The approval of Opdivo for the new indication was based on CHECKMATE-901, a randomized, open-label study in 608 patients with previously untreated unresectable or metastatic UC. Patients were randomized to Opdivo in combination with cisplatin and gemcitabine followed by Opdivo monotherapy vs. cisplatin-gemcitabine alone. The major outcome measures were overall survival (OS) and progression-free survival (PFS). Additional outcome measures were overall response rate (ORR) and duration of response (DOR).
  - Median OS was 21.7 months in the Opdivo group vs. 18.9 months in the comparator group (hazard ratio [HR] 0.78, 95% CI: 0.63, 0.96; p = 0.0171).
  - Median PFS was 7.9 months in the Opdivo group vs. 7.6 in the comparator group (HR 0.72, 95% CI: 0.59, 0.88; p = 0.0012).
  - The ORR was 57.6% (95% CI: 51.8, 63.2) in the Opdivo group vs. 43.1% (95% CI: 37.5, 48.9) in the comparator group.
  - The median DOR was 9.5 months (95% CI: 7.6, 15.1) in the Opdivo group vs. 7.3 months (95% CI: 5.7, 8.9) in the comparator group.
- For first-line unresectable or metastatic urothelial carcinoma, the recommended dose of Opdivo is 360 mg intravenously (IV) every 3 weeks, in combination with cisplatin and gemcitabine on the same day every 3 weeks, for up to 6 cycles. After completing up to 6 cycles of combination therapy, Opdivo as a single agent should be administered 240 mg every 2 weeks or 480 mg every 4 weeks until disease progression, unacceptable toxicity, or up to 2 years from first dose.
- Refer to the Opdivo drug label for dosing for all its other indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.